UPDATE: Baird Starts Allogene (ALLO) at Neutral

June 2, 2022 4:23 PM EDT
Get Alerts ALLO Hot Sheet
Price: $10.67 -1.2%

Rating Summary:
    15 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 6 | Down: 13 | New: 11
Join SI Premium – FREE
(Updated - June 3, 2022 6:55 AM EDT)

Baird analyst Jack Allen initiates coverage on Allogene (NASDAQ: ALLO) with a Neutral rating and a price target of $11.00.

The analyst comments "We're initiating coverage of Allogene, a leader in the allogeneic CAR-T space. While we believe the early response data from Allogene's CD19 programs is similar to that seen with the approved autologous CAR-T products (on an intention-to-treat basis), we expect durability of responses to Allogene's allogeneic assets will be the key area of debate moving forward. Given this dynamic, we are initiating with a Neutral rating and $11 price target, as we await additional color on the ALLO-501A pivotal study design, which should become available in mid-2022."

For an analyst ratings summary and ratings history on Allogene click here. For more ratings news on Allogene click here.

Shares of Allogene closed at $7.70 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Robert W Baird